References

ssmu

Бюллетень сибирской медицины

Bulletin of Siberian Medicine

1682-03631819-3684

Siberian State Medical University, the Ministry of Healthcare of the Russian Federation

10.20538/1682-0363-2020-1-180-189

ssmu-2698

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEW AND LECTURES

Молекулярно-генетические маркеры фибрилляции предсердий

Molecular genetic markers of atrial fibrillation

https://orcid.org/0000-0002-3002-2863

Понасенко

А. В.

Ponasenko

A. V.

https://orcid.org/0000-0002-4824-2418

Синицкий

М. Ю.

Sinitsky

M. Y.

Россия, 650000, г. Кемерово, пр. Советский, 18

18, Sovetsky Av., Kemerovo, 650000, Russian Federation

max-sinitsky@rambler.ru

https://orcid.org/0000-0002-9714-4080

Хуторная

М. В.

Khutornaya

M. V.

Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний (НИИ КПССЗ)РоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation

Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний (НИИ КПССЗ); Федеральный исследовательский центр угля и углехимии Сибирского отделения Российской академии наук (ФИЦ УУХ СО РАН)РоссияResearch Institute for Complex Issues of Cardiovascular Diseases; Federal Research Center of Coal and Coal Chemistry of the Siberian Branch the Russian Academy of SciencesRussian Federation

2020

16042020

191180189

2020

Понасенко А.В., Синицкий М.Ю., Хуторная М.В.

Ponasenko A.V., Sinitsky M.Y., Khutornaya M.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://bulletin.ssmu.ru/jour/article/view/2698

Фибрилляция предсердий (ФП) – наджелудочковая форма тахиаритмии, характеризующаяся нескоординированным возбуждением предсердий, проявляющимся в увеличении частоты их сокращения. Частота возникновения данной патологии напрямую коррелирует с возрастом пациентов и достигает 50% в старшей возрастной группе. Необходимость увеличения эффективности профилактических мероприятий обусловливает поиск маркеров, позволяющих оценивать индивидуальные риски развития заболевания. Среди таких маркеров наиболее перспективными являются полиморфные варианты ключевых генов, участвующих в патогенезе ФП. В данном обзоре обсуждены результаты изучения генетических маркеров развития данной патологии, а также возможность их использования в качестве предикторов ФП.

фибрилляция предсердийгенетический полиморфизмсердечно-сосудистые заболевания

atrial fibrillationgenetic polymorphismcardiovascular diseases

Работа выполнена при поддержке комплексной программы фундаментальных научных исследований СО РАН в рамках фундаментальной темы НИИ КПССЗ № 0546- 2015-0012 «Мультифокальный атеросклероз и коморбидные состояния. Особенности диагностики, управления рисками в условиях крупного промышленного региона Сибири».

The work was supported by the basic research program of the Siberian Branch of RAS as part of the research topic No. 0546-2015-0012 “Multifactorial atherosclerosis and comorbid conditions. Peculiarities of diagnosis and risk management in a big industrial region of Siberia”.

References1

Мазур Н.А. Фибрилляция и трепетание предсердий. М.: Медпрактика-М, 2003: 20.

Polovina M., Đikić D., Vlajković A., Vilotijević M., Milinković I., Ašanin M., Ostojić M., Coats A.J.S., Seferović P.M. Adverse cardiovascular outcomes in atrial fibrillation: validation of the new 2MACE risk score. Int. J. Cardiol. 2017; 249: 191–197. DOI: 10.1016/j.ijcard.2017.09.154.

Sun Y., Hu D. The link between diabetes and atrial fibrillation: cause or correlation? J. Cardiovasc. Dis. 2010; 1 (1): 10–11. DOI: 10.4103/0975-3583.59978.

Lloyd-Jones D.M., Wang T.J., Leip E.P., Larson M.G., Levy D., Vasan R.S., D’Agostino R.B., Massaro J.M., Beiser A., Wolf P.A., Benjamin E.J. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110 (9): 1042–1046. DOI: 10.1161/01.CIR.0000140263.20897.42.

Darbar D., Roden D.M. Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nat. Rev. Cardiol. 2013; 10 (6): 317–329. DOI: 10.1038/nrcardio.2013.53.

O’Neal W.T., Sangal K., Zhang Z.M., Soliman E.Z. Atrial fibrillation and incident myocardial infarction in the elderly. Clin. Cardiol. 2014; 37 (12): 750–755. DOI: 10.1002/clc.22339.

Winkel T.A., Hoeks S.E., Schouten O., Zeymer U., Limbourg T., Baumgartner I., Bhatt D.L., Steg P.G., Goto S., Röther J., Cacoub P.P., Verhagen H.J., Bax J.J., Poldermans D. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the reduction of atherothrombosis for continued health (REACH) registry. Eur. J. Vasc. Endovasc. Surg. 2010; 40 (1): 9–16. DOI: 10.1016/j.ejvs.2010.03.003.

Lee H.Y., Yang P.S., Kim T.H., Uhm J.S., Pak H.N., Lee M.H., Joung B. Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study. Sci. Rep. 2017; 7 (1): 12716. DOI: 10.1038/s41598-017-13061-4.

Одаренко Ю.Н., Рутковская Н.В., Горбунова Е.В., Хоменко Е.А., Кокорин С.Г., Барбараш О.Л. Применение биопротезов в хирургии митральных пороков: возможности отказа от антикоагулянтной терапии. Комплексные проблемы сердечно-сосудистых заболеваний. 2018; 7 (3): 72–82. DOI: 10.17802/2306-1278-2018-7-3-72-82.

Markides V., Schilling R.J. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart. 2003; 89 (8): 939–943. DOI: 10.1136/heart.89.8.939.

Hu Y.F., Chen Y.J., Lin Y.J., Chen S.A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 2015; 12 (4): 230–243. DOI: 10.1038/nrcardio.2015.2.

Никулина С.Ю., Шульман В.А., Кузнецова О.О., Аксютина Н.В., Шестерня П.А., Чернова А.А., Максимов В.Н., Куликов И.В., Устинов С.Н., Казаринова Ю.Л., Ромащенко А.Г., Воевода М.И. Клинико-генетические особенности фибрилляции предсердий. Рациональная фармакотерапия в кардиологии. 2008; 4 (2): 13–18.

Parvez B., Chopra N., Rowan S., Vaglio J.C., Muhammad R., Roden D.M., Darbar D. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J. Am. Coll. Cardiol. 2012; 59 (1): 49–56. DOI: 10.1016/j.jacc.2011.08.061.

Bapat A., Anderson C.D., Ellinor P.T., Lubitz S.A. Genomic basis of atrial fibrillation. Heart. 2018; 104 (3): 201–206. DOI: 10.1136/heartjnl-2016-311027.

Lubitz S.A., Yin X., Fontes J.D., Magnani J.W., Rienstra M., Pai M., Villalon M.L., Vasan R.S., Pencina M.J., Levy D., Larson M.G., Ellinor P.T., Benjamin E.J. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010; 304 (20): 2263–2269. DOI: 10.1001/jama.2010.1690.

Arnar D.O., Thorvaldsson S., Manolio T.A., Thorgeirsson G., Kristjansson K., Hakonarson H., Stefansson K. Familial aggregation of atrial fibrillation in Iceland. Eur. Heart J. 2006; 27 (6): 708–712. DOI: 10.1093/eurheartj/ehi727.

Christophersen I.E., Ravn L.S., Budtz-Joergensen E., Skytthe A., Haunsoe S., Svendsen J.H., Christensen K. Familial aggregation of atrial fibrillation: a study in Danish twins. Circ. Arrhythm. Electrophysiol. 2009; 2 (4): 378–383. DOI: 10.1161/CIRCEP.108.786665.

GWAS Catalog. URL: https://www.ebi.ac.uk/gwas/search?query=*&filter=recent (Accessed 25 December 2018).

Gudbjartsson D.F., Arnar D.O., Helgadottir A., Gretarsdottir S., Holm H., Sigurdsson A., Jonasdottir A., Baker A., Thorleifsson G., Kristjansson K., Palsson A., Blondal T., Sulem P., Backman V.M., Hardarson G.A., Palsdottir E., Helgason A., Sigurjonsdottir R., Sverrisson J.T., Kostulas K., Ng M.C., Baum L., So W.Y., Wong K.S., Chan J.C., Furie K.L., Greenberg S.M., Sale M., Kelly P., MacRae C.A., Smith E.E., Rosand J., Hillert J., Ma R.C., Ellinor P.T., Thorgeirsson G., Gulcher J.R., Kong A., Thorsteinsdottir U., Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007; 448 (7151): 353–357. DOI: 10.1038/nature06007.

Kaab S., Darbar D., van Noord C., Dupuis J., Pfeufer A., Newton-Cheh C., Schnabel R., Makino S., Sinner M.F., Kannankeril P.J., Beckmann B.M., Choudry S., Donahue B.S., Heeringa J., Perz S., Lunetta K.L., Larson M.G., Levy D., MacRae C.A., Ruskin J.N., Wacker A., Schömig A., Wichmann H.E., Steinbeck G., Meitinger T., Uitterlinden A.G., Witteman J.C., Roden D.M., Benjamin E.J., Ellinor P.T. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur. Heart. J. 2009; 30 (7): 813–839. DOI: 10.1093/eurheartj/ehn578.

Shi L., Li C., Wang C., Xia Y., Wu G., Wang F., Xu C., Wang P., Li X., Wang D., Xiong X., Bai Y., Liu M., Liu J., Ren X., Gao L., Wang B., Zeng Q., Yang B., Ma X., Yang Y., Tu X., Wang Q.K. Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population. Hum. Genet. 2009; 126 (6): 843–849. DOI: 10.1007/s00439-009-0737-3.

Delaney J.T., Jeff J.M., Brown N.J., Pretorius M., Okafor H.E., Darbar D., Roden D.M., Crawford D.C. Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PLoS One. 2012; 7 (2): e32338. DOI: 10.1371/journal.pone.0032338.

Olesen M.S., Bentzen B.H., Nielsen J.B., Steffensen A.B., David J.P., Jabbari J., Jensen H.K., Haunsø S., Svendsen J.H., Schmitt N. Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. BMC Med. Genet. 2012; 13: 24. DOI: 10.1186/1471-2350-13-24.

Nielsen J.B., Bentzen B.H., Olesen M.S., David J.P., Olesen S.P., Haunsø S., Svendsen J.H., Schmitt N. Gainof-function mutations in potassium channel subunit KCNE2 associated with early-onset lone atrial fibrillation. Biomark. Med. 2014; 8 (4): 557–570. DOI: 10.2217/bmm.13.137.

Li L., Shen C., Yao Z., Liang J., Huang C. Genetic variants of potassium voltage-gated channel genes (KCNQ1, KCNH2, and KCNE1) affected the risk of atrial fibrillation in elderly patients. Genet. Test. Mol. Biomarkers. 2015; 19 (7): 359–365. DOI: 10.1089/gtmb.2014.0307.

El Harchi A., Zhang H., Hancox J.C. The S140G KCNQ1 atrial fibrillation mutation affects ‘I(KS)’ profile during both atrial and ventricular action potentials. J. Physiol. Pharmacol. 2010; 61 (6): 759–764.

Hancox J.C., Kharche S., El Harchi A., Stott J., Law P., Zhang H. In silico investigation of a KCNQ1 mutation associated with familial atrial fibrillation. J. Electrocardiol. 2014; 47 (2): 158–165. DOI: 10.1016/j.jelectrocard.2013.12.004.

Olson T.M. et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 2006; 15 (14): 2185–2191. DOI: 10.1093/hmg/ddl143.

Yang Y. et al. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J. Hum. Genet. 2009; 54 (5): 277–283. DOI: 10.1038/jhg.2009.26.

Christophersen I.E., Olesen M.S., Liang B., Andersen M.N., Larsen A.P., Nielsen J.B., Haunsø S., Olesen S.P., Tveit A., Svendsen J.H., Schmitt N. Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation. Eur. Heart. J. 2013; 34 (20): 1517–1525. DOI: 10.1093/eurheartj/ehs442.

Grammer J.B., Bosch R.F., Kühlkamp V., Seipel L. Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation. J. Cardiovasc. Electrophysiol. 2000; 11 (6): 626–633. DOI: 10.1111/j.1540-8167.2000.tb00024.x

Brundel B.J., Van Gelder I.C., Henning R.H., Tuinenburg A.E., Wietses M., Grandjean J.G., Wilde A.A., Van Gilst W.H., Crijns H.J. Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J. Am. Coll. Cardiol. 2001; 37 (3): 926–932. DOI: 10.1016/s0735-1097(00)01195-5.

Olesen M.S., Refsgaard L., Holst A.G., Larsen A.P., Grubb S., Haunsø S., Svendsen J.H., Olesen S.P., Schmitt N., Calloe K. A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation. Cardiovasc. Res. 2013; 98 (3): 488–495. DOI: 10.1093/cvr/cvt028.

Low S.K., Takahashi A., Ebana Y., Ozaki K., Christophersen I.E., Ellinor P.T., AFGen Consortium, Ogishima S., Yamamoto M., Satoh M., Sasaki M., Yamaji T., Iwasaki M., Tsugane S., Tanaka K., Naito M., Wakai K., Tanaka H., Furukawa T., Kubo M., Ito K., Kamatani Y., Tanaka T. Identification of six new genetic loci associated with atrial fibrillation in the Japanese population. Nat. Genet. 2017; 49 (6): 953–958. DOI: 10.1038/ng.3842.

Olesen M.S., Andreasen L., Jabbari J., Refsgaard L., Haunsø S., Olesen S.P., Nielsen J.B., Schmitt N., Svendsen J.H. Very early-onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation. Heart Rhythm. 2014; 11 (2): 246–251. DOI: 10.1016/j.hrthm.2013.10.034.

Jeff J.M., Donahue B.S., Brown-Gentry K., Roden D.M., Crawford D.C., Stein C.M., Kurnik D. Genetic variation in the β1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. Am. Heart J. 2014; 167 (1): 101–108. DOI: 10.1016/j.ahj.2013.09.016.

Nicoulina S., Shulman V., Shesternya P., Chernova A., Salmina A., Issachenko O., Maksimov V., Voevoda M. Association of ADRB1 gene polymorphism with atrial fibrillation. Genet. Test. Mol. Biomarkers. 2010; 14 (2): 249–253. DOI: 10.1089/gtmb.2009.0100.

Parikh K.S., Piccini J.P. Pharmacogenomics of bucindolol in atrial fibrillation and heart failure. Curr. Heart Fail. Rep. 2017; 14 (6): 529–535. DOI: 10.1007/s11897-017-0364-6.

Шульман В.А., Никулина С.Ю., Дудкина К.В. Роль гена альфа-2-бета-адренорецепторов в генезе фибрилляции предсердий. Сибирское медицинское обозрение. 2009; 5 (59): 23–26.

Nair G.M., Nery P.B., Redpath C.J., Birnie D.H. The role of renin angiotensin system in atrial fibrillation. J. Atr. Fibrillation. 2014; 6 (6): 972. DOI: 10.4022/jafib.972.

Tsai C.T., Lai L.P., Lin J.L., Chiang F.T., Hwang J.J., Ritchie M.D., Moore J.H., Hsu K.L., Tseng C.D., Liau C.S., Tseng Y.Z. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004; 109 (13): 1640–1646. DOI: 10.1161/01.CIR.0000124487.36586.26.

Topal N.P., Ozben B., Hancer V.S., Tanrikulu A.M., Diz-Kucukkaya R., Fak A.S., Basaran Y., Yesildag O. Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation. J. Renin Angiotensin Aldosterone Syst. 2011; 12 (4): 549–556. DOI: 10.1177/1470320311399605.

Zhao L.Q., Wen Z.J., Wei Y., Xu J., Chen Z., Qi B.Z., Wang Z., Shi Y.Y., Liu S.W. Polymorphisms of renin-angiotensin-aldosterone system gene in Chinese Han patients with non-familial atrial fibrillation. PLoS One. 2015; 10 (2): e0117489. DOI: 10.1371/journal.pone.0117489.

Tsai C.T., Hwang J.J., Chiang F.T., Wang Y.C., Tseng C.D., Tseng Y.Z., Lin J.L. Renin-angiotensin system gene polymorphisms and atrial fibrillation: a regression approach for the detection of gene-gene interactions in a large hospitalized population. Cardiology. 2008; 111 (1): 1–7. DOI: 10.1159/000113419.

Ravn L.S., Benn M., Nordestgaard B.G., Sethi A.A., Agerholm-Larsen B., Jensen G.B., Tybjaerg-Hansen A. Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenet. Genomics. 2008; 18 (6): 525–533. DOI: 10.1097/FPC.0b013e3282fce3bd.

Liu T., Korantzopoulos P., Xu G., Shehata M., Li D., Wang X., Li G. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis. Europace. 2011; 13 (3): 346–354. DOI: 10.1093/europace/euq407.

Ueberham L., Bollmann A., Shoemaker M.B., Arya A., Adams V., Hindricks G., Husser D. Genetic ACE I/D polymorphism and recurrence of atrial fibrillation after catheter ablation. Circ. Arrhythm. Electrophysiol. 2013; 6 (4): 732–737. DOI: 10.1161/CIRCEP.113.000253.

Ma R., Li X., Su G., Hong Y., Wu X., Wang J., Zhao Z., Song Y., Ma S. Angiotensin-converting enzyme insertion/deletion gene polymorphisms associated with risk of atrial fibrillation: A meta-analysis of 23 case-control studies. J. Renin Angiotensin Aldosterone Syst. 2015; 16 (4): 793–800. DOI: 10.1177/1470320315587179.

Кускаева А.В., Никулина С.Ю., Чернова А.А., Аксютина Н.В., Кускаев А.П., Черкашина И.И. Роль полиморфизма I/D гена ACE в развитии фибрилляции предсердий. Кардиология. 2018; 58 (2): 5–9. DOI: 10.18087/cardio.2018.2.10079.

Feng W., Sun L., Qu X.F. Association of AGTR1 and ACE2 gene polymorphisms with structural atrial fibrillation in a Chinese Han population. Pharmazie. 2017; 72 (1): 17–21. DOI: 10.1691/ph.2017.6752.

Kim M., Guzik J. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 2005; 97 (7): 629–636. DOI: 10.1161/01.RES.0000183735.09871.61.

Шульман В.А., Никулина С.Ю., Дудкина К.В., Воевода М.И., Максимов В.Н., Аксютина Н.В., Чернова А.А., Злодеев К.В., Аллахвердян А.А. Роль гена NO-синтазы в генезе фибрилляции предсердий. Сибирское медицинское обозрение. 2011; 1 (67): 16–20.

Bedi M., McNamara D., London B., Schwartzman D. Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm. 2006; 3 (7): 808–812. DOI: 10.1016/j.hrthm.2006.03.002.

Fares F., Smith Y., Azzam N., Zafrir B., Lewis B.S., Amir O. The 894G Allele of the endothelial nitric oxide synthase 3 (eNOS) is associated with atrial fibrillation in chronic systolic heart failure. J. Atr. Fibrillation. 2012; 5 (4): 757. DOI: 10.4022/jafib.757.

Chen H., Chu H., Shi Y., Bhuyan S.S., Li J.P., Liu S.R., Yang J. Association between endothelial nitric oxide synthase polymorphisms and atrial fibrillation: a meta-analysis. J. Cardiovasc. Transl. Res. 2012; 5 (4): 528–534. DOI: 10.1007/s12265-012-9375-6.

Gensini F., Padeletti L., Fatini C., Sticchi E., Gensini G.F., Michelucci A. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing. Clin. Electrophysiol. 2003; 26 (1P2): 295–298. DOI: 10.1046/j.1460-9592.2003.00036.x.

Liggett S.B., Cresci S., Kelly R.J., Syed F.M., Matkovich S.J., Hahn H.S., Diwan A., Martini J.S., Sparks L., Parekh R.R., Spertus J.A., Koch W.J., Kardia S.L.R., Dorn G.W. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat. Med. 2008; 14 (5): 510–517. DOI: 10.1038/nm1750.

Kertai M.D., Li Y.W., Li Y.J., Shah S.H., Kraus W.E., Fontes M.L., Stafford-Smith M., Newman M.F., Podgoreanu M.V., Mathew J.P. G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers. Circ. Cardiovasc. Genet. 2014; 7 (5): 625–633. DOI: 10.1161/CIRCGENETICS.113.000451.

Liu L., Zhang L., Liu M., Zhang Y., Han X., Zhang Z. GRK5 polymorphisms and postoperative atrial fibrillation following coronary artery bypass graft surgery. Sci. Rep. 2015; 5: 12768. DOI: 10.1038/srep12768.

The authors declare that there are no conflicts of interest present.